Skip to main content

Table 3 The inter-relationship between clinico-pathological characteristics and lymphatic invasion (LVI D2-40 ) in patients with primary operable invasive ductal breast cancer

From: Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer

All patients (n = 360)

LVID2–40-ve

LVID2–40+ve

( P-value)

n = 233 (65%)

n = 127 (35%)

Age (≤50/ >50 years)

69/164

56/71

0.006

Size (≤20/ 21-50/ >50 mm)

129/97/7

56/65/6

0.038

Grade (I / II / III)

156/73/13

56/53/21

<0.001

Involved lymph node (0/1-3/ >3)

153/80

53/74

<0.001

ER status (no/yes)

102/131

69/58

0.056

PR status (no/yes)

118/115

76/51

0.095

HER2 status (no/yes)

193/40

96/31

0.099

Endocrine therapy (no/yes)

168/62

104/19

0.014

Chemotherapy (no/yes)

150/80

59/64

0.002

Tumour recurrence (no/local/distant/both)

199/5/28/1

72/12/39/4

<0.001

Alive/cancer death/non cancer death

141/39/53

48/58/21

0.059

Cancer specific survival (months)a

186(177–194)

134(120–149)

<0.001

Node-negative disease (n = 206)

n = 153 (74%)

n = 53 (26%)

 

Age (≤50/ >50 years)

42/111

25/28

0.008

Size (≤20/ 21-50/ >50 mm)

96/55/2

24/27/2

0.019

Grade (I / II / III)

33/53/67

1/20/32

0.002

ER status (no/yes)

32/48

40/34

0.082

PR status (no/yes)

38/42

43/31

0.189

HER2 status (no/yes)

130/23

38/15

0.032

Endocrine therapy (no/yes)

106/46

43/9

0.070

Chemotherapy (no/yes)

111/41

31/21

0.070

Tumour recurrence (no/local/distant/both)

137/4/11/1

33/4/14/2

<0.001

Alive/cancer death/non cancer death

99/18/36

25/17/11

0.266

Cancer specific survival (months)a

198(190–206)

153(131–174)

0.001

Triple-negative patients (n = 120)

n = 74(62%)

46(38%)

 

Age (≤50/ >50 years)

26/48

24/22

0.064

Size (≤20/ 21-50/ >50 mm)

42/28/4

21/23/2

0.367

Grade (I / II / III)

1/13/60

0/8/38

0.712

Involved lymph node (-ve/+ve)

52/22

18/28

0.001

Endocrine therapy (no/yes)

65/9

42/3

0.336

Chemotherapy (no/yes)

36/38

15/30

0.103

Tumour recurrence (no/local/distant)

64/0/10

24/3/19

<0.001

Alive/cancer death/non cancer death

48/13/13

18/24/4

0.217

Cancer specific survival (months)a

176(161–192)

122(96–147)

<0.001

  1. a = Mean (95% CI).